Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
REV-ERB/Autophagy Inhibitor
ARN5187 is a lysosomotropic ligand targeting REV-ERBĪ², known for its dual inhibitory effects on REV-ERB-mediated transcriptional regulation and autophagy. This compound exhibits significant lysosomotropic potency and has cytotoxic properties, leading to the induction of apoptosis. ARN5187 serves as a valuable tool for research into the mechanisms of autophagy and the role of REV-ERBĪ² in cellular processes. -
Autophagy Inhibitor
IITZ-02 is a lysosomotropic autophagy inhibitor that disrupts lysosomal function, leading to impaired autophagosomal degradation and increased autophagosome accumulation. This compound induces apoptosis through a mitochondria-mediated pathway by abolishing mitochondrial membrane potential. IITZ-02 exhibits potent antitumor activity in MDA-MB-231 xenograft mouse models, making it a valuable tool for cancer research applications focusing on the regulation of autophagy. -
CXCR-4 Inhibitor
SSB-2548 is a selective inhibitor of the chemokine receptor CXCR-4. It has demonstrated significant efficacy in inhibiting the proliferation and migration of acute myeloid leukemia cells, while also promoting apoptosis. Its favorable gastrointestinal absorption profile makes SSB-2548 a valuable tool for investigating the underlying mechanisms of leukemia and exploring potential therapeutic interventions. -
Autophagy Inhibitor
Erythrabyssin II is a potent late-stage autophagy inhibitor that selectively inhibits the fusion of autophagosomes and lysosomes. This compound promotes the accumulation of autophagic substrates without disrupting lysosomal pH or enzyme activity. Erythrabyssin II has demonstrated efficacy in suppressing ovarian cancer organoid growth and inducing apoptosis, making it a valuable tool for research in ovarian cancer studies. -
Autophagy Inhibitor
EAD1 TFA is an autophagy inhibitor that plays a critical role in the regulation of plant growth and development, particularly in maize. This compound is preferentially expressed in the xylem of immature corn ears, where it facilitates the transport of malic acid. Its function is essential for proper ear length and kernel development, with alterations in EAD1 TFA expression correlating with changes in malic acid content. EAD1 TFA represents a valuable tool for researchers investigating the genetic basis of crop yield improvement. -
Autophagy Inhibitor/Ionic Compound
Ammonium chloride is an ionic compound known for its role as an autophagy inhibitor. By inducing intracellular alkalization, it can disrupt lysosomal function and alter enzymatic activity, leading to metabolic acidosis. This compound is widely utilized in research applications focused on autophagy modulation and lysosomal pathway studies. -
Autophagy Inhibitor; p62 ZZ Domain Inhibitor
XRK3F2 is a selective inhibitor of the p62 (sequestosome-1) ZZ domain, demonstrating potent inhibition of autophagy processes. This compound effectively blocks TNFĪ±-induced signaling in bone marrow stromal cells and promotes apoptosis in multiple myeloma cells. XRK3F2 is valuable for research applications targeting multiple myeloma bone disease and acute myeloid leukemia, providing insights into cell survival mechanisms and autophagic regulation in hematological malignancies. -
Cytokinin Nucleoside/Autophagy Inhibitor
N6-Isopentenyladenosine, a cytokinin nucleoside, acts primarily as an autophagy inhibitor. This compound, derived from the mevalonate pathway, has demonstrated notable anti-melanoma activity. Additionally, it plays a critical role in RNA modification, enhancing the efficiency and accuracy of translation in certain tRNAs and regulating plant growth and differentiation. Research applications include investigations into autophagy-related mechanisms and the development of therapeutic strategies for melanoma. -
ATG7 Inhibitor
ATG7-IN-2 is a potent inhibitor of ATG7, demonstrating an IC50 of 0.089 Ī¼M. This compound effectively inhibits the autophagy marker LC3B, making it a valuable tool for studies involving autophagy modulation. Researchers can utilize ATG7-IN-2 to investigate the role of autophagy in various biological processes and disease states. -
Autophagy Inhibitor
DC-LC3in-D5 functions as an autophagy inhibitor by inhibiting the lipidation of LC3B. It effectively binds to LC3B and disrupts the interaction with LBP2, exhibiting an IC50 value of 200 nM. This compound is valuable in research focused on the modulation of autophagy, contributing to investigations of anti-HCV therapies and potential cancer treatments through autophagy inhibition. -
Autophagy Inhibitor
ATG7-IN-1 is a selective inhibitor of the autophagy-related protein ATG7, exhibiting an IC50 of 62 nM. This compound interferes with autophagy processes by disrupting the function of ATG7, making it a valuable tool for research in autophagy regulation. It is particularly useful for studies investigating the role of autophagy in various diseases, including cancer and neurodegenerative disorders. -
Autophagy Inhibitor
Autogramin-2 is a potent autophagy inhibitor that effectively blocks autophagy triggered by nutrient deprivation, demonstrating an IC50 of 0.27 Ī¼M, as well as autophagy induced by mTORC1 inhibition with Rapamycin, with an IC50 of 0.14 Ī¼M. This compound is valuable for studying the role of autophagy in cellular processes and various diseases, including cancer and neurodegeneration. Its ability to modulate autophagic pathways makes it an essential tool for researchers investigating autophagy's impact on cell survival and metabolism. -
Kif15/ULK1 Inhibitor
GW406108X is a selective inhibitor of Kif15 (Kinesin-12) and exhibits a significant inhibition of ULK1 kinase activity with a pIC50 of 6.37 (427 nM). This compound demonstrates potent autophagy inhibition, effectively blocking autophagic flux without impacting upstream signaling pathways such as mTORC1 and AMPK. GW406108X serves as a valuable tool in research focusing on autophagy regulation and related cellular processes. -
ATG7 Inhibitor
ATG7-IN-3 is a highly effective inhibitor of ATG7, exhibiting an IC50 of 0.048 Ī¼M. This compound disrupts autophagy by preventing the formation of LC3B puncta, a critical process in the autophagic pathway. Research applications include investigations into glioma and colon cancer, making it a valuable tool for studying the role of autophagy in cancer biology. -
mTOR Inhibitor/Autophagy Inducer
mTOR inhibitor-8 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), functioning through the interaction with FKBP12. This compound effectively suppresses mTOR activity and induces autophagy in A549 human lung cancer cells. It is a valuable tool for studying mTOR signaling pathways and the role of autophagy in cancer research. -
LRRK2 Inhibitor
LRRK2-IN-17 is a potent inhibitor of Leucine-rich repeat kinase 2 (LRRK2), with IC50 values of 3.5 nM and 3.3 nM for wild-type and G2019S mutant variants, respectively. Additionally, it exhibits inhibitory activity against RET kinase with an IC50 of 59 nM. This compound is relevant for research applications related to cancer and Parkinson's disease, making it a valuable tool for investigating the role of LRRK2 in these conditions. -
LRRK2 Inhibitor
Lu AF58786 is a selective inhibitor of LRRK2, demonstrating potent activity with an IC50 of 12 nM. It effectively inhibits both the LRRK2 G2019S and LRRK2 A2016T mutations, with IC50 values of 19 nM and 93 nM, respectively. Additionally, Lu AF58786 prevents the phosphorylation of LRRK2, Rab10, and Rab12 in human peripheral blood mononuclear cells. This compound is suitable for research applications focused on Parkinson's disease. -
LRRK2 Inhibitor
EB-42486 is a potent and highly selective inhibitor of the G2019S mutant variant of LRRK2, exhibiting an IC50 of less than 0.2 nM. This compound demonstrates significant biological activity in cellular models, making it a valuable tool for investigating the role of LRRK2 in Parkinson's disease. Researchers can utilize EB-42486 to explore potential therapeutic strategies aimed at modulating LRRK2 activity in neurodegenerative disorders. -
LRRK2 KinaseĀ Inhibitor
LRRK2-IN-7 is a potent and selective inhibitor of the LRRK2 kinase, exhibiting an IC50 of 0.9 nM. This compound demonstrates over 1000-fold selectivity against other kinases, ion channels, and cytochrome P450 enzymes. Due to its ability to penetrate the central nervous system (CNS), LRRK2-IN-7 is valuable for studies related to neurodegenerative diseases and the physiological roles of LRRK2 in cellular signaling pathways. -
LRRK2 Inhibitor
MK-1468 is a selective LRRK2 inhibitor known for its oral bioavailability and ability to cross the blood-brain barrier. This compound has demonstrated significant potential in studying the pathophysiology of Parkinson's disease, making it a valuable tool for researchers investigating therapeutic mechanisms and interventions in neurodegenerative disorders related to LRRK2 activity. -
LRRK2 Inhibitor
GNE-7915 tosylate is a potent and selective inhibitor of LRRK2, exhibiting an IC50 of 9 nM. This compound demonstrates effective brain penetration, making it a valuable tool for studying LRRK2-related pathways in neurological diseases. Its specificity allows for targeted research into the role of LRRK2 in conditions such as Parkinson's disease and other neurodegenerative disorders. -
LRRK2 Inhibitor
LRRK2-IN-2 is a potent and selective inhibitor of the Leucine-rich repeat kinase 2 (LRRK2) with an IC50 of less than 0.6 nM. This orally active compound demonstrates excellent brain penetration, making it valuable for studies focused on Parkinsonās disease. Its specificity and efficacy support a range of neurobiological research applications related to LRRK2's role in neurodegeneration. -
LRRK2 Inhibitor
LRRK2-IN-3 is a potent and selective inhibitor of LRRK2, exhibiting an IC50 of 2.6 nM in human peripheral blood mononuclear cells (PBMCs). This orally active compound demonstrates effective brain penetration, making it an invaluable tool for studying LRRK2's role in neurodegenerative disorders. Its application in Parkinson's disease research allows for deeper insights into disease mechanisms and therapeutic strategies targeting LRRK2 pathways. -
LRRK2 Inhibitor
LRRK2-IN-16 is a selective inhibitor of the LRRK2 kinase with an IC50 value of less than 5 Ī¼M. This compound is valuable for investigating neurodegenerative and autoimmune disorders, providing insights into the role of LRRK2 in these pathologies. Its use in research can enhance understanding of disease mechanisms and aid in the development of therapeutic strategies targeting LRRK2. -
G2019S-LRRK2 Kinase Inhibitor
LRRK2-IN-10 is a potent and mutation-selective inhibitor targeting the G2019S variant of LRRK2 kinase. It exhibits IC50 values of 11 nM and 5.2 nM for phosphorylated sites pS935 and pS1292, respectively, demonstrating its effectiveness in modulating LRRK2 activity. This compound is particularly valuable for research related to Parkinsonās disease, offering insights into the mechanisms of G2019S-LRRK2 in neurological contexts. -
LRRK2 Inhibitor
CZC-54252 hydrochloride is a potent and selective inhibitor of LRRK2, exhibiting IC50 values of 1.28 nM for wild-type and 1.85 nM for the G2019S mutant variant. This compound effectively attenuates G2019S LRRK2-induced neuronal injury, with an EC50 of approximately 1 nM, showcasing its neuroprotective properties. CZC-54252 hydrochloride is valuable for research applications focused on neurodegenerative diseases associated with LRRK2 modulation. -
LRRK2 Inhibitor
SRI-31255 is an orally active inhibitor of Leucine-rich repeat kinase 2 (LRRK2), exhibiting IC50 values of 520 nM and 427 nM for human wild-type and G2019S mutant forms, respectively. By binding to the ATP-binding pocket of LRRK2, SRI-31255 effectively inhibits kinase activity, providing neuroprotective effects. This compound is a valuable tool for research aimed at developing LRRK2-targeted therapies for Parkinson's disease. -
LRRK2 Inhibitor
LRRK2-IN-14 is a potent LRRK2 inhibitor with a remarkable IC50 of 6.3 nM specifically targeting the LRRK2(G2019S) mutation. This compound exhibits significant inhibitory activity against hERG with an IC50 of 22 Ī¼M. Notably, LRRK2-IN-14 demonstrates permeability across the blood-brain barrier, making it a valuable tool for studying neurodegenerative diseases related to LRRK2 dysregulation. Its pharmacological profile positions it as a promising candidate for research applications in Parkinson's disease and other related disorders. -
LRRK2 Inhibitor
LRRK2-IN-6 is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) with potent activity demonstrated by IC50 values of 4.6 Ī¼M for GS LRRK2 and 49 Ī¼M for wild-type LRRK2. This compound effectively inhibits autophosphorylation at Ser1292 and Ser925, key sites associated with LRRK2 activity. LRRK2-IN-6's ability to cross the blood-brain barrier makes it a valuable tool for research in neurodegenerative diseases linked to LRRK2 dysregulation. -
LRRK2 Inhibitor
SRI-29132 is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2). It exhibits significant activity in modulating LRRK2-related pathways, making it a valuable tool for investigating the pathophysiology of Parkinson's disease and the development of potential therapeutic strategies. Research utilizing SRI-29132 can provide insights into the role of LRRK2 in neurodegenerative processes and neuronal signaling. -
LRRK2 Inhibitor
LRRK2-IN-20 is a selective inhibitor of the leucine-rich repeat kinase 2 (LRRK2), exhibiting a pIC50 of 0.7921 nM. This compound is primarily utilized in the study of Parkinson's disease, enabling researchers to explore LRRK2's role in disease pathology and therapeutic interventions. Its potent inhibition provides a valuable tool for investigating the underlying mechanisms of neurodegeneration and potential treatment strategies. -
LRRK2 Inhibitor
LRRK2-IN-4 is a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), exhibiting an IC50 of 2.6 nM. This compound demonstrates good central nervous system penetration and oral bioavailability, making it a valuable tool for studying LRRK2's role in cellular signaling. LRRK2-IN-4 is particularly relevant for research into Parkinsonās disease, providing a means to explore therapeutic strategies targeting this kinase in related pathophysiological contexts. -
LRRK2 Inhibitor
PF-06455943 is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) with an IC50 of 3 nM. This compound also functions as a PET radioligand, making it valuable for imaging studies. PF-06455943 is primarily utilized in research investigating ADME/neuro pharmacokinetics and offers insights into pathophysiological mechanisms associated with Parkinson's disease (PD). -
LRRK2 Inhibitor
LRRK2-IN-5 is a selective inhibitor of the leucine-rich repeat kinase 2 (LRRK2), demonstrating potent inhibitory activity with IC50 values of 1.2 Ī¼M for GS LRRK2 and 16 Ī¼M for wild-type LRRK2. This compound effectively inhibits LRRK2 autophosphorylation at the Ser1292 and Ser925 sites, making it a valuable tool for studying LRRK2's role in various neurological disorders. Additionally, LRRK2-IN-5 is capable of crossing the blood-brain barrier, facilitating its application in central nervous system research. -
LRRK2 Kinase Inhibitor
(R,R)-LRRK2-IN-7 is a selective LRRK2 kinase inhibitor, exhibiting a potent inhibitory activity with an IC50 of 0.9 nM. This compound demonstrates over 1000-fold selectivity against various other kinases, ion channels, and CYP enzymes, making it a valuable tool for studies involving LRRK2-associated pathologies. Its ability to penetrate the central nervous system (CNS) enhances its relevance for research applications in neurodegenerative diseases. -
LRRK2 Inhibitor
LY2023-001 is a selective inhibitor of the G2019S mutation in LRRK2, exhibiting a potent inhibitory activity with an IC50 of 12.9 nM. This compound interacts with critical residues, forming stable hydrogen bonds with Glu1948 and Ala1950 in the G2019S LRRK2 protein. It serves as a valuable tool for investigating the role of LRRK2 signaling in neurodegenerative disorders, facilitating research in cellular models and drug development for Parkinson's disease. -
LRRK2 Inhibitor
LRRK2-IN-12 is a potent inhibitor of LRRK2, effectively targeting G2019S (IC50=0.45 nM) and wild-type LRRK2 (IC50=1.1 nM), with a similar affinity for the wild-type enzyme in the presence of ADP (IC50=0.46 nM). This compound is valuable for research into neurodegenerative diseases, particularly in investigating the role of LRRK2 in Alzheimer's Disease. Its high specificity and low nanomolar activity make it an essential tool for exploring LRRK2-related pathways and therapeutic interventions. -
Autophagy Inhibitor
Leonurine hydrochloride is an alkaloid derived from Leonurus artemisia, acting primarily as an autophagy inhibitor. This compound exhibits notable anti-oxidative and anti-inflammatory properties, making it a valuable tool for research into cellular stress responses and inflammatory processes. It is particularly useful for studying the implications of autophagy modulation in various biological contexts, including neurodegenerative diseases and cancer. -
autophagy inhibitor
Monensin sodium is an ionophore and inhibitor of autophagy commercially used in livestock feed. It inhibits autophagy, interfering with the fusion of the autophagosome and the lysosome. - Parthenolide ((-)-Parthenolide) is a sesquiterpene lactone which occurs naturally in the plant feverfew (Tanacetum parthenium).
-
MAO-B inhibitor
Quercetin inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C. -
HMG-CoA reductase inhibitor
Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM. -
HDAC inhibitor
Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. -
Calcium channel antagonist
Felodipine is a 1,4-dihydropyridine antagonist and calcium channel protein inhibitor.
-
HMGB1 release inhibitor
Ethyl pyruvate is a simple derivative of the endogenous metabolite, pyruvic acid. Ethyl pyruvate is an anti-inflammatory agent. -
Autophagy Inhibitor
Reserpine acts as an inhibitor of vesicular monoamine transporter 2 (VMAT2), thereby influencing neurotransmitter storage and release. This compound is widely utilized in research studies focusing on autophagy inhibition and its implications in various neurodegenerative disorders. Additionally, reserpine's effects on monoamine levels make it a valuable tool in the investigation of psychiatric conditions and the biochemical pathways involved in these diseases. -
Autophagy Inhibitor
Leonurine is an alkaloid derived from Leonurus artemisia, functioning predominantly as an autophagy inhibitor. This compound exhibits notable antioxidative and anti-inflammatory properties, making it valuable for research focused on cellular stress responses and neuroprotection. Its ability to modulate autophagy can be explored in studies related to aging, neurodegenerative diseases, and inflammation-related conditions. -
Topoisomerase I Inhibitor
Irinotecan hydrochloride is a potent inhibitor of topoisomerase I, an enzyme crucial for DNA replication and transcription. This compound exhibits significant anti-tumor activity, primarily in the treatment of colorectal cancers. Its mechanism involves the stabilization of the enzyme-DNA complex, leading to apoptosis in cancer cells. Irinotecan hydrochloride is widely utilized in cancer research to elucidate cellular response mechanisms and to develop novel therapeutic strategies.
